Shattuck Labs Inc

NASDAQ:STTKUnited States

Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. It is conducting a Phase IA/B clinical trial in patients with acute myeloid leukemia (AML) and HR-MDS. It has completed the Phase IA dose-escalation portion of this clinical trial and are enrolling patients in the Phase IB expansion cohorts evaluating SL-172154 in combination with azacitidine in frontline HR-MDS or frontline TP53 mutant (TP53m) AML. It has developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions.

Contact Information

Headquarters

500 W. 5Th Street, Suite 100AUSTIN, TX, United States 78701

Phone

512-900-4690

Fax

---

Executives

Independent Chairman of the Board

George Golumbeski

Chief Executive Officer, Co-Founder, Director

Taylor Schreiber

Chief Financial Officer

Andrew Neill

Deputy General Counsel, Vice President - Intellectual Property

Stephen Stout

Chief Business Officer

Casi Deyoung